Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 2.2/5
Remegen (9995 HK)
Watchlist
Contact IR
209
Analysis
Health Care
•
China
RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.
more
Watchlist
Contact IR
Filings
Presentations
Events
Refresh
Exchange Announcement •
16 Jan 2025 10:50
Inside Information-Estimated 2024 Annual Results
Attachment
Exchange Announcement •
10 Jan 2025 12:56
List Of Directors And Their Roles And Functions
Attachment
Exchange Announcement •
10 Jan 2025 12:48
Poll Results Of The 2025 First Extraordinary General Meeting
Attachment
Exchange Announcement •
23 Dec 2024 10:09
Proxy Form For Use At The 2025 First Extraordinary General Meeting
Attachment
Exchange Announcement •
23 Dec 2024 10:04
Notice Of 2025 First Extraordinary General Meeting
Attachment
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.45.1
x